DUETACT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DUETACT (DUETACT).
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
| Metabolism | Pioglitazone is extensively metabolized by hydroxylation and oxidation, primarily via CYP2C8 and to a lesser extent CYP3A4. Glimepiride is metabolized by CYP2C9. |
| Excretion | Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites). |
| Half-life | Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes. |
| Protein binding | Pioglitazone: >99% bound to serum albumin. Glimepiride: >99.5% bound to serum albumin. |
| Volume of Distribution | Pioglitazone: 0.25 L/kg; glimepiride: 0.18 L/kg. Both indicate limited extravascular distribution, consistent with high protein binding. |
| Bioavailability | Pioglitazone: oral bioavailability 83%. Glimepiride: oral bioavailability 100% (highly absorbed). |
| Onset of Action | Oral: Pioglitazone, peak effect on fasting glucose in 2-4 weeks; glimepiride, reduction in postprandial glucose begins within 1-2 hours, peak effect on fasting glucose in 2-3 days. |
| Duration of Action | Pioglitazone: 24 hours (due to active metabolites); glimepiride: 24 hours (supports once-daily dosing). Clinical note: steady-state glucose control achieved after 3-4 weeks for pioglitazone. |
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR <25 mL/min/1.73 m² (due to metformin component); not recommended if GFR <30 due to potential for lactic acidosis (if metformin-containing); glimepiride-containing: caution if CrCl <30 due to prolonged half-life; avoid if CrCl <30. |
| Liver impairment | Contraindicated in Child-Pugh class C (due to pioglitazone); avoid with active liver disease; monitor ALT; if ALT >2.5x ULN, do not initiate; if ALT >3x ULN during therapy, discontinue. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no specific pediatric dosing available. |
| Geriatric use | Start at lower doses (e.g., 15/2 mg) due to reduced renal function; caution with glimepiride due to increased hypoglycemia risk; monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DUETACT (DUETACT).
| Breastfeeding | No data available on excretion in human milk. Pioglitazone and glimepiride are present in rat milk; unknown if excreted in human milk. M/P ratio not determined. Breastfeeding not recommended due to potential for neonatal hypoglycemia. |
| Teratogenic Risk | FDA Pregnancy Category C. Pioglitazone: limited human data; in animal studies, delayed parturition, embryotoxicity, and reduced fetal weight at doses >2 times MRHD. Glimepiride: sulfonylurea; prolonged severe hypoglycemia reported in neonates exposed near term; risk of hyperinsulinemia and macrosomia. Second and third trimester use associated with neonatal hypoglycemia. |
■ FDA Black Box Warning
Thiazolidinediones, including pioglitazone, may cause or exacerbate congestive heart failure. DUETACT should be initiated at the lowest approved dose and dose escalation should be gradual. Patients should be observed for signs and symptoms of heart failure.
| Serious Effects |
["Known hypersensitivity to pioglitazone, glimepiride, or any component of DUETACT","Diabetic ketoacidosis with or without coma","NYHA Class III or IV heart failure"]
| Precautions | ["Congestive heart failure","Increased risk of bladder cancer with pioglitazone use","Hypoglycemia","Hepatic effects","Cardiovascular effects","Edema","Weight gain","Macular edema","Fractures","Ovulation in premenopausal anovulatory women"] |
| Food/Dietary | DUETACT should be taken with the first main meal of the day to reduce gastrointestinal side effects and ensure consistent absorption. Grapefruit and grapefruit juice may interact with pioglitazone; avoid excessive consumption. High-fat meals can delay absorption of pioglitazone but do not significantly alter overall exposure. Alcohol consumption increases hypoglycemia risk; advise moderation or avoidance. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c. Fetal surveillance including growth ultrasound and nonstress test in third trimester. Monitor neonatal blood glucose for 24-48 hours after delivery for hypoglycemia. Consider ECG monitoring for potential hypoglycemia-induced arrhythmias. |
| Fertility Effects | Pioglitazone: in animal studies, no effect on fertility at doses up to 4 times MRHD. Glimepiride: no human data; animal studies showed no impaired fertility. Possible restoration of ovulation in anovulatory women with insulin resistance, increasing pregnancy risk. |
| Clinical Pearls | DUETACT is a fixed-dose combination of pioglitazone (a thiazolidinedione) and glimepiride (a sulfonylurea). Monitor liver function before and periodically during therapy; pioglitazone can cause hepatotoxicity. Assess for edema and heart failure risk, as pioglitazone may precipitate or exacerbate heart failure. Glimepiride carries a risk of severe hypoglycemia, especially in elderly or debilitated patients. Avoid use in patients with type 1 diabetes or diabetic ketoacidosis. |
| Patient Advice | Take DUETACT with the first main meal of the day to reduce gastrointestinal upset and optimize absorption. · Report symptoms of liver injury: dark urine, jaundice, persistent nausea, or abdominal pain. · Be aware of signs of hypoglycemia: shakiness, sweating, confusion, rapid heart rate, or blurred vision; always carry a fast-acting sugar source. · Weigh yourself regularly and report rapid weight gain or swelling in ankles/feet, which may indicate fluid retention. · Avoid alcohol consumption as it can increase the risk of hypoglycemia from glimepiride. · Do not skip meals, especially after taking the medication, to prevent hypoglycemia. · Inform all healthcare providers that you are taking DUETACT, especially before surgery or diagnostic procedures involving contrast dyes. · Do not use if you have active bladder cancer or a history of bladder cancer; pioglitazone is associated with increased risk. |